227 related articles for article (PubMed ID: 36361954)
1. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
[TBL] [Abstract][Full Text] [Related]
2. Discovering Tuberosin and Villosol as Potent and Selective Inhibitors of AKT1 for Therapeutic Targeting of Oral Squamous Cell Carcinoma.
Adnan M; Jairajpuri DS; Chaddha M; Khan MS; Yadav DK; Mohammad T; Elasbali AM; Abu Al-Soud W; Hussain Alharethi S; Hassan MI
J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887580
[TBL] [Abstract][Full Text] [Related]
3. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase.
Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI
OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).
Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L
Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766
[TBL] [Abstract][Full Text] [Related]
5. Identification of high-affinity inhibitors of pyruvate dehydrogenase kinase-3: towards therapeutic management of cancer.
Mohammad T; Arif K; Alajmi MF; Hussain A; Islam A; Rehman MT; Hassan I
J Biomol Struct Dyn; 2021 Feb; 39(2):586-594. PubMed ID: 31903847
[TBL] [Abstract][Full Text] [Related]
6. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.
Anastasiou D; Yu Y; Israelsen WJ; Jiang JK; Boxer MB; Hong BS; Tempel W; Dimov S; Shen M; Jha A; Yang H; Mattaini KR; Metallo CM; Fiske BP; Courtney KD; Malstrom S; Khan TM; Kung C; Skoumbourdis AP; Veith H; Southall N; Walsh MJ; Brimacombe KR; Leister W; Lunt SY; Johnson ZR; Yen KE; Kunii K; Davidson SM; Christofk HR; Austin CP; Inglese J; Harris MH; Asara JM; Stephanopoulos G; Salituro FG; Jin S; Dang L; Auld DS; Park HW; Cantley LC; Thomas CJ; Vander Heiden MG
Nat Chem Biol; 2012 Oct; 8(10):839-47. PubMed ID: 22922757
[TBL] [Abstract][Full Text] [Related]
7. In-Silico Analysis of Phytocompounds of
Qais FA; Alomar SY; Imran MA; Hashmi MA
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144527
[TBL] [Abstract][Full Text] [Related]
8. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds.
Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y
Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759
[TBL] [Abstract][Full Text] [Related]
9. Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity.
Chen C; Wang T; Wu F; Huang W; He G; Ouyang L; Xiang M; Peng C; Jiang Q
Drug Des Devel Ther; 2014; 8():1195-210. PubMed ID: 25214764
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
[TBL] [Abstract][Full Text] [Related]
11. Computer-aided identification of a novel pyruvate kinase M2 activator compound.
Li Y; Bao M; Yang C; Chen J; Zhou S; Sun R; Wu C; Li X; Bao J
Cell Prolif; 2018 Dec; 51(6):e12509. PubMed ID: 30133040
[TBL] [Abstract][Full Text] [Related]
12. Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment.
Sarfraz I; Rasul A; Jabeen F; Sultana T; Adem Ş
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296707
[TBL] [Abstract][Full Text] [Related]
13. Searching for Novel Anaplastic Lymphoma Kinase Inhibitors: Structure-Guided Screening of Natural Compounds for a Tyrosine Kinase Therapeutic Target in Cancers.
Adnan M; Koli S; Mohammad T; Siddiqui AJ; Patel M; Alshammari N; Bardakci F; Elasbali AM; Hassan MI
OMICS; 2022 Aug; 26(8):461-470. PubMed ID: 35925819
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study.
Marciniec K; Rzepka Z; Chrobak E; Boryczka S; Latocha M; Wrześniok D; Beberok A
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985481
[TBL] [Abstract][Full Text] [Related]
15. Cancer metabolism control by natural products: Pyruvate kinase M2 targeting therapeutics.
El-Far AH; Al Jaouni SK; Li X; Fu J
Phytother Res; 2022 Aug; 36(8):3181-3201. PubMed ID: 35794729
[TBL] [Abstract][Full Text] [Related]
16. 2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2.
Yoon YJ; Kim YH; Jin Y; Chi SW; Moon JH; Han DC; Kwon BM
Cancer Lett; 2018 Oct; 434():42-55. PubMed ID: 30009856
[TBL] [Abstract][Full Text] [Related]
17. Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.
Ye X; Sun Y; Xu Y; Chen Z; Lu S
Med Chem; 2016; 12(7):613-620. PubMed ID: 26951145
[TBL] [Abstract][Full Text] [Related]
18. Serine is a natural ligand and allosteric activator of pyruvate kinase M2.
Chaneton B; Hillmann P; Zheng L; Martin ACL; Maddocks ODK; Chokkathukalam A; Coyle JE; Jankevics A; Holding FP; Vousden KH; Frezza C; O'Reilly M; Gottlieb E
Nature; 2012 Nov; 491(7424):458-462. PubMed ID: 23064226
[TBL] [Abstract][Full Text] [Related]
19. Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics.
Yang C; Alam A; Alhumaydhi FA; Khan MS; Alsagaby SA; Al Abdulmonem W; Hassan MI; Shamsi A; Bano B; Yadav DK
Molecules; 2022 May; 27(10):. PubMed ID: 35630545
[TBL] [Abstract][Full Text] [Related]
20. A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia.
Kim DJ; Park YS; Kim ND; Min SH; You YM; Jung Y; Koo H; Noh H; Kim JA; Park KC; Yeom YI
Mol Cells; 2015 Apr; 38(4):373-9. PubMed ID: 25813626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
